Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Amgen

Anthem

Cigna

Johnson & Johnson

Eli Lilly

Merck

UnitedHealth Group

Shares of UnitedHealth Group Inc. soared 10.2% in morning trading, enough to pace the Dow Jones Industrial Average's gainers, as the uncertain election outcome is seen as a boon to the health care sector. The stock's price gain of $32.65 was adding about 215 points to the Dow's price, while the Dow was up 547 points, or 2.0%.

Health care stocks soar, add more than 350 points to the Dow's price

Biogen Inc. (NASDAQ: BIIB) shares rocketed up on Wednesday after briefing documents from the U.S.

Is Biogen Setting Up for a Big Alzheimer's Win?

Biogen's stock jumped after the Food and Drug Administration staff said they have enough data to support approval of the company's experimental Alzheimer's drug Aducanumab.

Biogen's stock jumps 30% after FDA staff says it has enough data to support approving Alzheimer's drug

Biogen stock rocketed Wednesday on the potential a Food and Drug Administration advisory committee would recommend approval of a controversial Alzheimer's treatment called aducanumab. The post Biogen Surges As FDA Panel Mulls Controversial Alzheimer's Drug appeared first on Investor's Business Daily.

Biogen Surges As FDA Panel Mulls Controversial Alzheimer's Drug

Biogen Inc (NASDAQ: BIIB) has an imminent stock catalyst in the form of an Adcom meeting for its Alzheimer's treatment candidate aducanumab, which it is co-developing with Japan's Eisai Co., Ltd (Pink: ESALY). Significant Binary Event For Biogen: The FDA's Peripheral and Central Nervous System Drugs Advisory Committee is scheduled to meet Friday to discuss Biogen's BLA for aducanumab solution for intravenous infusion in the treatment of Alzheimer's disease.

What Biogen Investors Should Know Ahead Of Adcom Meeting On Alzheimer's Candidate

CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (Nasdaq: BIIB) announced positive data from the 24-week systemic lupus erythematosus (SLE) portion of the Phase 2 LILAC study (part A) demonstrating that BIIB059 (anti-BDCA2) was associated with a statistically significant reduction in total active joint count. The study evaluated the efficacy and safety of BIIB059, a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) expressed exclusively on plasmacytoid dendritic cells. These data, along with the previously reported findings from the cutaneous lupus erythematosus (CLE) portion of the LILAC study, will be presented at the American College of Rheumatology's ACR Convergence 2020, being held virtually from November 5-9, 2020.

Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting

Mastercard

Their long-term prospects are what really matter.

Why 2 of Warren Buffett's 3 Worst-Performing Stocks in October Are Great Picks to Buy Right Now

Apple

Alibaba

Intel

Simon Property Group

According to GuruFocus Baskets statistics, the six most-popular stocks placed in GuruFocus users' Halloween candy baskets as of Friday are Intel Corp. (NASDAQ:INTC), Biogen Inc. (NASDAQ:BIIB), Apple Inc. (NASDAQ:AAPL), Facebook Inc. (NASDAQ:FB), Simon Property Group Inc. (NYSE:SPG) and Alibaba Group Holding Ltd. (NYSE:BABA).

6 Popular Stocks in GuruFocus Users' Candy Baskets

CAMBRIDGE, Mass. and TOKYO, Oct. 30, 2020 (GLOBE NEWSWIRE) --  Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the European Medicines Agency (EMA) has confirmed it has accepted for review, following a standard timetable, the Marketing Authorization Application (MAA) for aducanumab, an investigational treatment for Alzheimer's disease. Clinical data from patients with Mild Cognitive Impairment due to Alzheimer's disease and mild Alzheimer's disease demonstrate that treatment with aducanumab resulted in the removal of amyloid beta and better clinical outcomes. If approved, aducanumab would become the first therapy to reduce the clinical decline in patients with Alzheimer's disease.

European Medicines Agency Accepts Biogen's Aducanumab Marketing Authorization Application for Alzheimer's Disease

Revenues are declining due to generic competition. The pipeline of potential new therapies is broad.

Biogen Aducanumab Committee Danger And Opportunity

The company has struggled with drug pipeline progress, but it is still confident in its ability to provide long-term returns.

2 Fumbles and 1 Gift in Biogen's Latest Earnings Report

Alexion Pharma

Gilead Sciences

Moderna

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The short interest data are out for October 15, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Major Biotechs Have Short Sellers Looking Both Ways

A much-anticipated Alzheimer's drug candidate could be Biogen's new growth driver.

Why an Upcoming FDA Meeting Is Critical for Biogen Stock

Check Point Software Technologies

NetEase

According to the All-in-one Screener's "Customized Ranking" feature, a Premium feature of GuruFocus, the top three high-quality stocks based on Joel Greenblatt (Trades, Portfolio)'s "Magic Formula" rank are Check Point Software Technologies Ltd. (NASDAQ:CHKP), Biogen Inc. (NASDAQ:BIIB) and NetEase Inc. (NASDAQ:NTES).

Top 3 High-Quality Stocks Based on Greenblatt Magic Formula Rank

Biogen Inc (NASDAQ: BIIB) reported fairly solid third-quarter results Wednesday, sending its shares higher.  Against this backdrop, an analyst at SVB Leerink said the key to outperformance for the company is a positive regulatory ruling on its controversial Alzheimer's treatment candidate aducanumab.

Why Biogen's Fortunes Hinge On Aducanumab Approval

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q3 2020 Results - Earnings Call Transcript

BYD Company Limited

Systemic difference had led to divergence in control of COVID-19 cases in major economies which should be reflected in our portfolio. Warren Buffett had shown the way by his investment into electric vehicles and pharmaceutical companies.

Finding The Buffett Balance For Your Portfolio As Major Economies Diverge

Biogen (BIIB) beats third-quarter estimates for both earnings and sales. Tecfidera generics hurts sales, resulting in guidance cut.

Biogen (BIIB) Q3 Earnings Top, Tecfidera Generics Hurt Sales

When Biogen Inc. (NASDAQ: BIIB) reported its third-quarter financial results before the markets opened on Wednesday, the firm said that it had $8.84 in earnings per share (EPS) and $3.38 billion in revenue.

The Good, the Bad, the Ugly of Biogen's Q3

Shares of Biogen were down 0.1% in premarket trading on Wednesday after the company missed earnings expectations for the quarter. The drug maker had earnings of $701.50, or $4.46 per share, in the third quarter of 2020, a 55% decline in earnings compared with the $1,545.90, or $8.39 per share, it reported in the same quarter a year ago.

Biogen's earnings tumble 55% in the third quarter of 2020

Biogen earnings and sales fell less than expected in the third quarter, but the biotech giant cut full-year guidance. BIIB stock was little changed.

Biogen Earnings Beat, But Full-Year Guidance Cut

Shares of Biogen (NASDAQ:BIIB) rose 3% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 3.60% year over year to $8.84, which beat the estimate of $8.13.

Biogen: Q3 Earnings Insights

SAN JUAN, Puerto Rico, Oct. 20, 2020 /PRNewswire/ -- Abarca, a pharmacy benefit manager (PBM) that is disrupting the industry with a new approach to technology and business practices released a new case study detailing a value-based agreement with Biogen Inc. (NASDAQ: BIIB) for Avonex®...

Abarca Details First Value-Based Agreement For Medicaid Members Prescribed Biogen Products

Biogen (NASDAQ: BIIB) unveils its next round of earnings this Wednesday, October 21. Here is Benzinga's everything-that-matters guide for the earnings announcement.

Biogen's Earnings Outlook

Biogen has embraced Ionis antisense technology for neurology targets.

News for Biogen Stock (BIIB)